What the latest ARES-G3 launch and earnings beat mean for Waters (WAT)

Waters (WAT) just rolled out its ARES-G3 Rheometer while also reporting fourth quarter results that topped expectations and came with positive sales and earnings guidance for the next few quarters.

Even with the ARES-G3 launch and an earnings beat in the background, Waters’ share price has been under pressure, with a 30 day share price return of 9.33% decline and a 1 year total shareholder return of 20.26% decline, suggesting recent sentiment has cooled after a stronger multi year run.

If this kind of product driven story has your attention, it can be useful to widen your search and look at 34 healthcare AI stocks identified by the Simply Wall St screener as another way to find potential opportunities in related areas.

With the shares down over the past year despite annual revenue of US$3.17b and net income of US$642.63m, plus a modelled intrinsic discount of about 31%, is Waters quietly undervalued here, or is the market already pricing in future growth?

Most Popular Narrative: 25.3% Undervalued

Against Waters' last close of $297.54, the most followed narrative sees fair value at about $398.05, framing the recent sell off as potentially out of sync with its long term earnings story.

The planned combination with BD's Biosciences and Diagnostic Solutions business is expected to accelerate entry into biologics, precision medicine, and cell/gene therapy markets, segments with expanding analytical needs, unlocking new addressable markets and providing a multi-year revenue synergy opportunity, directly impacting future revenues and EPS growth.

Curious how this tie up, recurring revenue mix, and richer future earnings multiple all feed into that higher fair value line? The full narrative lays out the detailed growth, margin and valuation assumptions behind the $398.05 figure, including how a higher discount rate still supports that outcome and what kind of earnings profile would need to show up for the model to stay intact.

Result: Fair Value of $398.05 (UNDERVALUED)

However, this hinges on smooth integration of BD's businesses and steady demand, while weaker funding in academic and government labs could easily derail that potential upside.

Another View: Rich P/E Keeps Expectations High

While one model points to Waters trading about 30.6% below an estimated fair value, the current P/E of 45.4x tells a different story. That is well above the US Life Sciences industry at 33.5x, the peer average at 24.3x, and a fair ratio of 25.9x that the market could move towards over time.

This gap means you are paying a high price today for expected growth, which can work out if the story plays out as hoped, but leaves less room for error if earnings or sentiment wobble. Which signal do you put more weight on: the discount to fair value or the premium P/E?

Next Steps

If the mix of optimism and caution in this story feels familiar, consider acting promptly and reviewing the data yourself, starting with 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Waters has sparked your interest, do not stop here. Broaden your watchlist with other high quality ideas that might suit different goals and risk levels.

• Target stability first and check out 67 resilient stocks with low risk scores that could help you keep potential drawdowns more contained.
• Hunt for value by scanning 50 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them.
• Get early to potential future leaders by reviewing our screener containing 23 high quality undiscovered gems before the wider market pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.